Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX001S vs ustekinumab in moderate-to-severe plaque psoriasis
CTR20211036Phase 3Completed
- Sponsor
- Qyuns Therapeutics
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab biosimilar QX001S in psoriasis, sponsored by Qyuns Therapeutics. Started May 2021; status: completed.
02
Drugs
ustekinumab biosimilar QX001S
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20211036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211036.